Arrowhead’s Plozasiran Cuts Acute Pancreatitis Risk by Up to 100% in Phase 3 Severe Hypertriglyceridemia Trials
Arrowhead plans sNDA filing by end of 2026.
/ 9 items
#ARWR↓
Biogen’s Tau Drug Diranersen Shows Promise in Phase 2 but Misses Primary Endpoint
Despite missing the primary endpoint, the drug advances to Phase 3 in 2027 with a favorable safety profile.
Sarepta Hits Early Win With New siRNA Drugs for Rare Muscle Diseases – Beating Rivals on Delivery and Safety
Sarepta just shared first test results for two new medicines aimed at rare muscle diseases FSHD1 and DM1. Early data show the drugs reach high levels in muscle safely, with no serious side effects. Shares jumped.
Arrowhead Gene Drug Doubles Weight Loss in Obesity Trial
Arrowhead Pharmaceuticals' (ARWR) ARO-INHBE gene-silencing drug combined with Zepbound doubles weight loss in obese diabetes patients, targeting dangerous visceral and liver fat more effectively.
Wave Life Sciences' Obesity Drug Shows Promising Fat Loss Without Muscle Decline
Wave Life Sciences' WVE-007 demonstrates 9.4% visceral fat reduction with muscle preservation in Phase 1 trial, earning positive analyst ratings and buy recommendations.
FDA Grants Breakthrough Therapy Status to Arrowhead’s Plozasiran for Severe High Triglycerides
Arrowhead Pharmaceuticals received FDA Breakthrough Therapy designation for plozasiran, a promising treatment aimed at lowering dangerously high triglyceride levels in adults with severe hypertriglyceridemia.